← 返回

使用病毒载体向原代免疫细胞进行基因转导的优化条件

英文原题:Optimized conditions for gene transduction into primary immune cells using viral vectors.

查看英文原题

Optimized conditions for gene transduction into primary immune cells using viral vectors.

PubMed 2023/07/31(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)T细胞疗法已成为一种有前景的抗癌治疗方式。其在血液系统肿瘤中的疗效相当显著。由于其优异的临床结果,包括T细胞、自然杀伤(NK)细胞和巨噬细胞在内的基因修饰细胞疗法正在学术界和工业界被积极研究。

然而,制备CAR免疫细胞的方案过于复杂,因此如何高效生产强效的CAR免疫细胞仍不清楚。为了制造有效的CAR免疫细胞,我们不仅需要了解如何获得高感染性的病毒颗粒,还需要了解如何将CAR基因转导至免疫细胞中。在本文中,我们从方法学角度提供了关于spinoculation的详细信息,这是将基因转导至免疫细胞中最著名的方案之一。

我们的数据表明,基因转导显著依赖于离心的速度和持续时间、病毒颗粒的浓度和数量、polybrene的浓度以及被感染的免疫细胞数量。

此外,我们研究了用于浓缩病毒上清液的最佳聚乙二醇(PEG)溶液,以及转染至293T细胞以产生高滴度病毒颗粒的最佳DNA比例。

本研究为利用病毒载体实际生产基因修饰免疫细胞提供了有用信息。

展开英文摘要原文

Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising modality for anti-cancer treatment. Its efficacy is quite remarkable in hematological tumors. Owing to their excellent clinical results, gene- modified cell therapies, including T cells, natural killer (NK) cells, and macrophages, are being actively studied in both academia and industry.

However, the protocol to make CAR immune cells is too complicated, so it is still unclear how to efficiently produce the potent CAR immune cells. To manufacture effective CAR immune cells, we need to be aware of not only how to obtain highly infective viral particles, but also how to transduce CAR genes into immune cells. In this paper, we provide detailed information on spinoculation, which is one of the best known protocols to transduce genes into immune cells, in a methodological view.

Our data indicate that gene transduction is significantly dependent on speed and duration of centrifugation, concentration and number of viral particles, the concentration of polybrene, and number of infected immune cells.

In addition, we investigated on the optimal polyethylene glycol (PEG) solution to concentrate the viral supernatant and the optimized DNA ratios transfected into 293T cells to produce high titer of viral particles.

This study provides useful information for practical production of the gene-modified immune cells using viral vectors.

论文信息

作者
Kim Y、Lee DY、Choi JU、Park JS、Lee SM、Kang CH、Park CH
第一作者单位
Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, PO Box 107, Daejeon, 34114, Republic of Korea.South Korea
通讯作者单位
Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, PO Box 107, Daejeon, 34114, Republic of Korea. chpark@krict.re.kr.South Korea
文献类型
非美国政府资助研究
期刊
Scientific reports2023 Jul 31
原文标识
PubMed 37524755 · DOI 10.1038/s41598-023-39597-2